Adrenergic Transporters
Adrenergic transporters (NET) are sodium- and chloride-dependent members of the solute carrier family 6 (SLC6) widely distributed throughout the brain within noradrenergic neuronal plasma membranes. They are responsible for re-uptake of adrenalin and noradrenalin.
Adrenergic Transporter Inhibitors |
|
|---|---|
| Cat. No. | 产品名称/活性 |
| 2831 | Bupropion hydrochloride |
| Non-selective inhibitor of dopamine and noradrenalin transporters | |
| 3067 | Desipramine hydrochloride |
| Selective inhibitor of noradrenalin transporters | |
| 4798 | (S)-Duloxetine hydrochloride |
| Potent 5-HT and NA reuptake inhibitor; also blocks dopamine reuptake | |
| 7841 | Imipramine hydrochloride |
| Potent inhibitor of 5-HT and noradrenalin transporters; promotes immunostimulatory tumor microenvironment | |
| 1588 | Indatraline hydrochloride |
| Potent noradrenalin uptake inhibitor; also inhibits 5-HT and dopamine uptake | |
| 1025 | Nisoxetine hydrochloride |
| Noradrenalin re-uptake inhibitor | |
| 1992 | Nomifensine |
| Potent noradrenalin and dopamine uptake inhibitor. Antidepressant | |
| 1982 | Reboxetine mesylate |
| Potent and selective noradrenalin uptake inhibitor; orally active | |
| 2175 | Tetrabenazine |
| Potent inhibitor of vesicular monoamine transport; depletes noradrenalin stores | |
| 2011 | Tomoxetine hydrochloride |
| Potent and selective noradrenalin re-uptake inhibitor | |
| 2917 | Venlafaxine hydrochloride |
| 5-HT and NA reuptake inhibitor (SNRI) | |
Substrates |
|
| Cat. No. | 产品名称/活性 |
| 5169 | Noradrenaline bitartrate |
| Endogenous adrenergic hormone and neurotransmitter | |
Other |
|
| Cat. No. | 产品名称/活性 |
| 6717 | FFN 270 |
| Fluorescent substrate for NET and VMAT2 | |
Adrenergic transporters (NET) are sodium- and chloride-dependent members of the solute carrier family 6 (SLC6) widely distributed throughout the brain within noradrenergic neuronal plasma membranes. They are responsible for the re-uptake of adrenalin, noradrenalin and (to a lesser extent) dopamine from the synaptic cleft back into vesicles for storage until later use, resulting in the termination of neurotransmitter action.
Adrenergic transporters contain the following structural motifs: 12-TM domains, extracellular loops, cytoplasmic C- and N-termini and putative phosphorylation sites. A role for NETs has been proposed in attention deficit disorder, substance abuse, neurodegenerative disorders and clinical depression.